Effective clinical research requires a continuous stream of data, but gathering real-world data isn’t always easy. It can be particularly tricky for pharmaceutical manufacturer researchers to connect with practicing oncologists. Community oncologists have many demands on their time and may not be available to participate in clinical research when you need them most. However, their […]

Emerging Oncology Trends Dramatic advances within the last decade have reshaped the global oncology market. A record number of new cancer drugs have received regulatory approval. Some of these treatments, such as immunotherapies, have permanently altered the way we approach cancer treatment. Yet while the global oncology market has enjoyed many triumphs, the industry continues […]

Immunotherapies have become a standard treatment for many patients with cancer. While these agents can be highly effective and associated with durable responses and improved long-term survival, they are also associated with a unique and potentially serious adverse event profile. Appropriate management of immune-related adverse events (irAEs) is essential for successful treatment with immunotherapies. To […]

While hundreds of clinical trials in lung cancer are completed each year, results from many trials will not be publicly released or published in a peer-reviewed journal. According to a study published in JAMA Network Open, results from as many as 25% of lung cancer clinical trials are never published. Researchers evaluated phase II and […]

While cyclin-dependent kinase (CDK)4/6 inhibitors have become a mainstay of treatment for patients with hormone receptor-positive (HR+), HER2-negative (HER2–) metastatic breast cancer (mBC), many patients still receive first-line treatment with chemotherapy, even in the absence of visceral crisis. Lacking head-to-head clinical trials comparing treatment approaches, a recent meta-analysis compared results from phase II and III […]

MorphoSys AG announced the combination of the CD19-targeted antibody tafasitamab with lenalidomide resulted in a statistically significant improvement in best objective response rate (ORR) compared with a real-world data-matched control cohort of lenalidomide alone in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This announcement was based on results from the retrospective observational matched-control cohort […]

According to a recent study conducted by Memorial Sloan Kettering Cancer Center, rates of Clostridioides difficile infection (CDI) are higher in patients with cancer than in healthy adults. This study used patient data from 93,566 patients in the SEER-Medicare database, including both healthy patients and patients with either solid tumors or hematologic malignancies diagnosed between […]

Although clinicians and drug manufacturers have always touted the value of certain treatments, cost-effectiveness hasn’t always been an integral part of the pharma market. However, priorities have shifted in recent years and value-based pricing has begun to dominate the US pharma market. As market access shifts, pharma companies must change their business model or risk […]

At Aptitude Health, we strive to understand patterns of care that affect cancer patients not enrolled in clinical trials. We identify factors influencing prescribing habits that shape best practices and positively impact patient care. CASES Summits are regional events where approximately 60 oncologists and hematologists from large community practices, along with leading scientific experts, gather […]

Guidelines from the National Comprehensive Cancer Network (NCCN) provide the foundation for treatment of breast cancer in the United States. However, as many as 1 in 5 patients receive treatment regimens that are not recommended by the NCCN, according to a recent study published in the Journal of the National Comprehensive Cancer Network. In this […]